Serological, clinical and epidemiological aspects of Lyme borreliosis in Mures County, Romania

Open access


Lyme borreliosis (LB) is the most frequent infection transmitted by ticks from the Ixodes genus, both in the United States of America (USA), and in Europe. The objectives of this study were the monitoring of the incidence and clinical manifestations of the disease in Mures County, Romania. Material and method. The study was conducted over a period of two years, January 1st 2010 -December 31st 2011, on a number of 120 consecutive patients. The definite or probable diagnosis of LB was established on the Centers for Disease Control and Prevention (CDC, Atlanta, USA) criteria, and on the European Union Concerted Action on Lyme borreliosis (EUCALB). ELISA and Western-Blot techniques were used for identification of IgM and IgG antiBb from the serum and CSF. Results. There were 44 cases in 2010 and 76 cases in 2011. According to the case definition, 106 cases were confirmed as LB and 14 were probable. LB was more frequently diagnosed in children, young adults and adults, compared to the over 60 years old age group. The incidence of disease was higher in women patients, 68 (56.66%) compared to men - 52 patients (43.33%), with a higher proportion in people coming from an urban setting, 78 patients (65%), compared to people coming from rural settings 42 patients (35%). Clinical manifestations were acute, like erythema migrans (EM) in 64.16% of the patients, neurological in 22.5% of the patients, joint related in 1.66% of the patients and cardiac in 0.83% of the cases. Conclusions. In Mures County we have observed an increased incidence of this disease in 2011 vs. 2010. The predominant clinical manifestations were the acute dermatological and neurological ones.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Stanek G Fingerle V Hunfeld KP Jaulhac B Kaiser R Krause A et al. Lyme borreliosis: clinical case definition for diagnosis and management in Europe. Clin Microbiol Infect. 2011 Jan;17(1):69-79 DOI: 10.1111/j.1469-0691.2010.03175.x

  • 2. Wright WF Riedel DJ Talwani R Gilliam BL. Diagnosis and Management of Lyme disease. Am Fam Physician. 2012 Jun 1; 85(11):1086-93

  • 3. Wormser GP Brisson D Liveris D Hanincora K Sandigursky S et al. Borrelia burgdorferi genotype predicts the capacity for hematogenous dissemination during early Lyme disease. J Infect Dis. 2008 Nov 1;198(9):1358-64 DOI: 10.1086/592279

  • 4. Wormser GP Dattwyler RJ Shapirro ED Halperin JJ Steere AC Klempner MS et al. The clinical assessment treatment and prevention of Lyme disease human granulocytic anaplasmosis and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006 Nov 1;43(9):1089-134 DOI: 10.1086/508667

  • 5. Coipan EC Vladimirescu AF: Ixodes ricinus ticks (Acari: Ixodidae): vectors for Lyme disease spirochetes in Romania. Exp Appl Acarol. 2011 Jul;54(3):293-300 DOI: 10.1007/s10493-011-9438-4

  • 6. Lindgren E Jaenson TGT: Lyme borreliosis in Europe. Influences of climate and climate change epidemiology ecology and adaptation measures World Health Organization Regional Office for Europe Copenhagen Denmark. 2006;5-24 [ assets/pdf_file/0006/96819/E89522.pdf]

  • 7. European Concerted Action on Lyme Borreliosis. Diagnosis: Case Definition EUCALB: []

  • 8. Wilske B Fingerle V Schulte-Spechtel U. Microbiological and serological diagnosis of Lyme borreliosis. FEMS Immunol Med Microbiol. 2007;49(1):13-21. Review DOI: 10.1111/j.1574-695X.2006.00139.x

  • 9. Centrul Național de Supraveghere şi Control al Bolilor Transmisibile - Boala Lyme - metodologie de supraveghere: Lyme borreliosis. [ ro/cnscbt/index.php?option=com_docman&task=cat_ view&gid=34&Itemid=10] [in Romanian]

  • 10. Centers for Disease Control and Prevention United States: Effect of electronic laboratory reporting on the burden of Lyme disease surveillance: New Jersey 2001-2006. MMWR. 2008 Jan;57(2):42-5

  • 11. Hristea A Hristescu S Ciufecu C Vasile A: Seroprevalence of Borrelia burgorferi in Romania. Eur J Epidemiol. 2001;17(9):891-6 DOI: 10.1023/A:1015600729900

  • 12. Semenza JC Suk JE Estevez V Ebi KL Lindgren E. Mapping Climate Change Vulnerabilities to Infectious Disease in Europe. Environ Health Perspect. 2012 Mar;120(3):385-92 DOI: 10.1289/ehp.1103805

  • 13. Stanek G Strle F. Lyme borreliosis: a European perspective ondiagnosis and clinical management. Curr Opin Infect Dis. 2009 Oct;22(5):450-4 DOI: 10.1097/ QCO.0b013e32832ee880

  • 14. Rizzoli A Hauffe HC Carpi G Vourch GI Neseler M Rosa R. Lyme borreliosis in Europe. Eurosurveillance. 2011 Jul;16(27):1-6

  • 15. Halperin JJ Shapiro ED Logigian EL Belman AL Dotevall L et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007 Jul;69(1):91-102 DOI: 10.1212/01. wnl.0000265517.66976.28

  • 16. Țilea B Chiriac C Țilea I Urcan R Tripon G Gliga M. Diagnostic therapeutic and evolutive particularities of Lyme disease. Rev Romana Med Lab. 2009 Jun;15(2):55-60

  • 17. O’Connel S. Lyme borreliosis: current issues in diagnosis and management. Curr Opin Infect Dis. 2010 Jun;23(3):231-5 DOI: 10.1097/ QCO.0b013e32833890e2

  • 18. Ljostad U Skogvoll E Eikeland R Skarpaas T et al. Oral doxycycline versus intravenous ceftriaxon for European Lyme neuroborreliosis: a multricentric non-inferiority double blind randomised trial. Lancet Neurol. 2008 Aug;7(8):690-5 DOI: 10.1016/S1474-4422(08)70119-4

  • 19. Smith R Takkinnen J. Lyme borreliosis: Europe-wide coordinated surveillance and action nedeed? Euro Surveill. 2006 Jun;11(6):E060622.1

  • 20. Skogman BH Glimåker K Nordwall M Vrethem M Ödkvist L Forsberg P. Long-term clinical outcome after Lyme neuroborreliosis in childhood. Pediatrics. 2012 Aug;130(2):262-9 DOI: 10.1542/peds.2011-3719

  • 21. Albrecht P Henke N Lehmann HC Macht S Hefter H et al. A case of relapsing -remitting neuroborreliosis? Challenges in the differential diagnosis of recurrent myelitis. Case Rep Neurol. 2012 Jan;4(1):47-53 DOI: 10.1159/000337223

  • 22. Fallon BA Levin ES Schweitzer PJ Hardesty D. Inflammation and central nervous system Lyme disease. Neurobiol Dis. 2010 Mar;37(3):534-41. DOI: 10.1016/j.nbd.2009.11.016

  • 23. Wormser GP Nadelman RB Schwartz I.The amber theory of Lyme arthritis: initial description and clinical implications. Clin Reumatol. 2012 Jun;31(6):989-94 DOI: 10.1007/s10067-012-1964-x

  • 24. Puius YA Kalish RA. Lyme arthritis: pathogenesis clinical presentation and management. Infect Dis North Am. 2008 Jun;22(2):289-300 DOI: 10.1016/j. idc.2007.12.014

  • 25. Costello JM Alexander ME Greco KM Perez AR Laussen PC. Lyme carditis in children: presentation predictive factors and clinical course. Pediatrics. 2009 May;123(5):835-41 DOI: 10.1542/peds.2008-3058

  • 26. Lo R Meuzies DJ Archer H Cohen TJ.J.Complete heart block due to Lyme carditis: Invasive Cardiol. 2003 Jun;15(6):367-9

  • 27. Koene R Boulware DR Kemperman M Konety SH Groth M et al. Acute hearth failure from lyme carditis. Circ Heart Fail. 2012 Mar;5(2):e24-6 DOI: 10.1161/ CIRCHEARTFAILURE.111.965533

Journal information
Impact Factor

IMPACT FACTOR 2018: 0.800
5-year IMPACT FACTOR: 0.655

CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2018: 0.194
Source Normalized Impact per Paper (SNIP) 2018: 0.306

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 234 144 1
PDF Downloads 102 70 0